| Zheng, Kai |
NCT06442852: Study on the Relationship Between Peripheral Blood miRNA and Risk and Severity of Alzheimer's Disease |
|
|
| Recruiting | N/A | 500 | RoW | exposure | Jiajie Chen | Alzheimer Disease, MicroRNAs | 12/26 | 12/26 | | |
| Fang, Baijun |
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 85 | RoW | Pomalidomide, Dexamethasone | Qilu Pharmaceutical Co., Ltd. | Multiple Myeloma, Recurrent or Refractory | 06/22 | 12/23 | | |
| Recruiting | 3 | 240 | RoW | Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone | Nanjing IASO Biotechnology Co., Ltd. | Multiple Myeloma | 08/27 | 12/30 | | |
NCT06508983: A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients |
|
|
| Recruiting | 3 | 360 | RoW | SG301 Injection, SG301 placebo, pomalidomide, dexamethasone | Hangzhou Sumgen Biotech Co., Ltd. | Relapsed/Refractory Multiple Myeloma | 03/27 | 03/28 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
| Recruiting | 2 | 120 | RoW | Etoposide, Cyclophosphamide, Mecapegfilgrastim, day 2, Mecapegfilgrastim, day 5 | Qiu Lugui, Jiangsu Hengrui Pharmaceuticals Co.,Ltd | Multiple Myeloma, Lymphoma | 03/24 | 09/24 | | |
| Recruiting | 2 | 50 | RoW | Selinexor (80mg/d), ATG-010, Selinexor (100mg/d), Pegylated liposomal doxorubicin, PLD, Dexamethasone, Dex, Cyclophosphamide, CTX | Chunyan Sun, MD | Multiple Myeloma | 12/24 | 12/24 | | |
NCT05611853: Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies |
|
|
| Terminated | 1/2 | 9 | RoW | BN301, STRO-001 | BioNova Pharmaceuticals (Shanghai) LTD. | B-cell Lymphoma, Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma | 12/23 | 12/23 | | |
| Active, not recruiting | 1/2 | 121 | RoW | CAR-BCMA T Cells | CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University | Multiple Myeloma | 12/24 | 12/25 | | |
NCT04674514: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 48 | RoW | APG-2575, Rd, Lenalidomide +Dexamethasone | Ascentage Pharma Group Inc. | Multiple Myeloma | 01/24 | 05/24 | | |
| Completed | 1/2 | 272 | Europe, Canada, Japan, US, RoW | Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone | Takeda, Takeda Development Center Americas, Inc. | Multiple Myeloma | 07/24 | 11/24 | | |
NCT05365100: A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL |
|
|
| Withdrawn | 1/2 | 174 | RoW | BN102, AS-1763 | BioNova Pharmaceuticals (Shanghai) LTD. | CLL/SLL, NHL | 07/24 | 07/24 | | |
NCT05719701: Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 80 | RoW | ICP-490, Dexamethasone | Beijing InnoCare Pharma Tech Co., Ltd. | Relapsed and/or Refractory Multiple Myeloma | 07/25 | 12/25 | | |
NCT05271682: A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma |
|
|
| Recruiting | 1 | 40 | RoW | FHND6091 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | Multiple Myeloma | 12/23 | 12/24 | | |
NCT06574568: A Study of YKST02 in Participants with Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1 | 70 | RoW | YKST02, YKST02 for Injection | Excyte Biopharma Ltd | Relapsed or Refractory Multiple Myeloma | 12/26 | 06/27 | | |
| Recruiting | 1 | 140 | RoW | TQB2934 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Multiple Myeloma | 10/24 | 10/25 | | |
NCT05363800: Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma |
|
|
| Recruiting | 1 | 198 | RoW | HRS-3738 | Jiangsu HengRui Medicine Co., Ltd. | Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma | 10/24 | 12/24 | | |
| Active, not recruiting | N/A | 482 | RoW | | Takeda | Multiple Myeloma, Neoplasms, Plasma Cell | 09/25 | 09/25 | | |
